![](https://library.celltelligence.com/wp-content/uploads/2021/11/Cellectis_Cytovia_Partnership.png)
$0
Cellectis – Cytovia Partnership Expands to Include China
On Thursday, November 18, Cellectis and Cytovia Therapeutics announced (press release) the expansion of their TALEN gene-edited iPSC-derived NK and CAR-NK partnership to enable broader collaboration in China through Cytovia’s joint venture CytoLynx Therapeutics. Below, Celltelligence provides insights on how Cellectis could benefit from the expanded collaboration.